Drug Trial Radar · NCT06159101
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
304
Planned (sponsor's estimate)
Start
Nov 28, 2023
Primary completion
May 28, 2024
Study completion May 28, 2024
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Dec 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects
Conditions
- Healthy Male Volunteers
Interventions
HLX13Drug
A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.
CN-sourced ipilimumabDrug
A single dose (0.3 mg/kg) of CN-sourced ipilimumab via intravenous infusion.
EU-sourced ipilimumab groupDrug
A single dose (0.3 mg/kg) of EU-sourced ipilimumab via intravenous infusion.
US-sourced ipilimumab groupDrug
A single dose (0.3 mg/kg) of US-sourced ipilimumab via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum concentration-time curve from time 0 to infinity (AUC0-inf)Time frame: Up to Day 90
- Maximum (peak) serum drug concentration (Cmax)Time frame: Up to Day 90
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Anhui, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.